Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

por Thalange, Nandu, Gundgaard, Jens, Parekh, Witesh, Tutkunkardas, Deniz
Publicado 2019

The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemogl...

por Haluzík, Martin, Fulcher, Greg, Pieber, Thomas R., Bardtrum, Lars, Tutkunkardas, Deniz, Rodbard, Helena W.
Publicado 2018

Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK

por Thalange, Nandu, Aldhouse, Natalie Valerie Jane, Kitchen, Helen, Howard, Daniel, Tutkunkardas, Deniz, Håkan-Bloch, Jonas
Publicado 2017

The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two r...

por Thalange, Nandu, Deeb, Larry, Klingensmith, Georgeanna, Franco, Denise R., Bardtrum, Lars, Tutkunkardas, Deniz, Danne, Thomas
Publicado 2019

Clinical inertia in basal insulin-treated patients with type 2 diabetes – Results from a retrospective database study in Japan (JDDM 43)

por Satoh, Jo, Andersen, Marc, Bekker Hansen, Brian, Larsen Thorsted, Brian, Tutkunkardas, Deniz, Zacho, Mette, Maegawa, Hiroshi
Publicado 2018

Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)...

por Pollock, Richard F., Heller, Simon, Pieber, Thomas R., Woo, Vincent, Gundgaard, Jens, Hallén, Nino, Luckevich, Maria, Tutkunkardas, Deniz, Zinman, Bernard
Publicado 2019

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

por Pollock, Richard F., Valentine, William J., Marso, Steven P., Gundgaard, Jens, Hallén, Nino, Hansen, Lars L., Tutkunkardas, Deniz, Buse, John B.
Publicado 2018

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

por Pollock, Richard F., Valentine, William J., Marso, Steven P., Andersen, Andreas, Gundgaard, Jens, Hallén, Nino, Tutkunkardas, Deniz, Magnuson, Elizabeth A., Buse, John B.
Publicado 2019